CD antigens 2001

Abstract

The most recent Human Leucocyte Differentiation Antigen Workshop ("HLDA7") took place in 2000 in Harrogate, UK and the proceedings are about to be published (Leucocyte Typing VII). New Sections were introduced in this Workship (Dendritic cells, Stem/progenitor cells, Erythroid cells and Carbohydrate Structures) and monoclonal antibodies were selected for which at least some molecular data were already available (to avoid "blind" screening of reagents against known specificities). A total of more than 80 new CD specificities were established (previously the average was less than 30 new CD specificities per Workshop) and these are listed in this article. There is already evidence for the existence of many new leucocyte surface molecules for study at the next HLDA Workshop (in Adelaide in 2004), and we have listed in this article a number of such potential CD candidates (identified following the production of monoclonal antibodies or via gene cloning). There are also today an increasing number of lineage- and/or stage-restricted leucocyte-associated molecules localised within the cell cytoplasm (or nucleus): they will certainly prove of intense in the future for many laboratories studying human haematopoietic cells (regardless of whether a new "intracellular CD" categorisation scheme is devised for such molecules).

Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy

“…The antibodies most commonly used in diagnostic hematopathology are briefly described below. Additional information about each cluster of differentiation can be found at ''Protein Reviews on the Web,'' a web site maintained by the National Cancer Institute, and in numerous books and literature reviews (92)(93)(94)(95)(96)(97)(98).…”

Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues

“…In addition, this initiative has not only assisted clinicians worldwide in diagnosis and therapy by providing independent confirmation of antibody specificity, but also has resulted in a universal nomenclature scheme [1][2][3].…”

CXCR4 chemokine receptors (CD184) and α4β1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis)

“…More recent studies demonstrated that a chemokine, stromal cell-derived factor-1 [SDF-1, also termed CXCL12 according to a new classification system (Zlotnik & Yoshie, 2000)], plays a key role in the trafficking and homing of CD34 + cells to the marrow (Wright et al, 2002). SDF-1 induces HSC (Kim & Broxmeyer, 1998;Imai et al, 1999;Jo et al, 2000) and acute myeloid leukaemia (AML) cell migration (Mohle et al, 1998;Voermans et al, 2002) in vitro by binding to a G-protein-coupled receptor, termed CXCchemokine receptor R4 (CXCR4) that was designated CD184 during the most recent Human Leucocyte Differentiation Antigen Workshop (Mason et al, 2001). HSC are highly selective in their migratory response to SDF-1 (Wright et al, 2002).…”